| Condensed Consolidated Statements Of Operations | |
| Related party revenue | |
| Technology and license revenue | 3K |
| Grant revenue | |
| Total revenues | |
| Operating expenses: | |
| Research and development | 2K |
| General and administrative | 2.15M |
| Restructuring charge | |
| Total operating expenses | 2.15M |
| Loss from operations | -2.15M |
| Interest income and other income, net | -4K |
| Loss from continuing operations before income taxes | |
| Income tax benefit for continuing operations | |
| Loss from continuing operations | |
| Discontinued Operations: | |
| Income (loss) from discontinued operations | |
| Gain on sale of discontinued operations | |
| Income tax expense for discontinued operations | |
| Income from discontinued operations | |
| Net income (loss) | |
| Net income (loss) attributable to non-controlling interests | |
| Net income (loss) attributable to Maxygen, Inc. | -2.13M |
| Basic and diluted net income (loss) per share: | |
| Continuing operations | |
| Discontinued operations | |
| Attributable to Maxygen, Inc. | -0.08 |
| Shares used in basic and diluted net income (loss) per share calculations | |